{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:29:16Z","timestamp":1772119756730,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s10928-023-09882-8","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T02:01:32Z","timestamp":1691719292000},"page":"77-87","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population pharmacokinetic\/pharmacodynamic modeling of nifekalant injection with varies dosing plan in Chinese volunteers: a randomized, blind, placebo-controlled study"],"prefix":"10.1007","volume":"51","author":[{"given":"Juanjuan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Chai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyuan","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"issue":"6","key":"9882_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.4330\/wjc.v3.i6.169","volume":"3","author":"IN Pantazopoulos","year":"2011","unstructured":"Pantazopoulos IN, Troupis GT, Pantazopoulos CN, Xanthos TT (2011) Nifekalant in the treatment of life-threatening ventricular tachyarrhythmias. World J Cardiol 3(6):169\u2013176. https:\/\/doi.org\/10.4330\/wjc.v3.i6.169","journal-title":"World J Cardiol"},{"issue":"1","key":"9882_CR2","first-page":"469","volume":"274","author":"R Sato","year":"1995","unstructured":"Sato R, Koumi S, Hisatome I, Takai H, Aida Y, Oyaizu M, Karasaki S, Mashiba H, Katori R (1995) A new class III antiarrhythmic drug, MS-551, blocks the inward rectifier potassium channel in isolated guinea pig ventricular myocytes. J Pharmacol Exp Ther 274(1):469\u2013474","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"9882_CR3","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S0008-6363(96)00049-1","volume":"31","author":"J Cheng","year":"1996","unstructured":"Cheng J, Kamiya K, Kodama I, Toyama J (1996) Differential effects of MS-551 and E-4031 on action potentials and the delayed rectifier K+ current in rabbit ventricular myocytes. Cardiovasc Res 31(6):963\u2013974","journal-title":"Cardiovasc Res"},{"issue":"13","key":"9882_CR4","doi-asserted-by":"publisher","first-page":"e012511","DOI":"10.1161\/JAHA.119.012511","volume":"8","author":"J Hu","year":"2019","unstructured":"Hu J, Yu J, Chen Q, Hu J, Huang Q, Xia Z, Xia Z, Ju Z, Yuan P, Fan S, Xiong Q, Zhu B, Huang L, You C, Bao H, Wu Y, Cheng X, Li J, Marian AJ, Hong K (2019) Efficacy of nifekalant in patients with Wolff-Parkinson-White syndrome and atrial fibrillation: electrophysiological and clinical findings. J Am Heart Assoc 8(13):e012511. https:\/\/doi.org\/10.1161\/JAHA.119.012511","journal-title":"J Am Heart Assoc"},{"issue":"Suppl 1","key":"9882_CR5","doi-asserted-by":"publisher","first-page":"P291","DOI":"10.1186\/cc9711","volume":"15","author":"N Harayama","year":"2011","unstructured":"Harayama N, Nihei S, Isa Y, Arai H, Shinjou T, Nagata K, Ueki M, Aibara K, Kamochi M (2011) Comparison of nifekalant and amiodarone for resuscitation after cardiopulmonary arrest due to shock-resistant ventricular fibrillation. Crit Care 15(Suppl 1):P291. https:\/\/doi.org\/10.1186\/cc9711","journal-title":"Crit Care"},{"issue":"3","key":"9882_CR6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.joa.2016.01.004","volume":"32","author":"M Suzuki","year":"2016","unstructured":"Suzuki M, Nagahori W, Mizukami A, Matsumura A, Hashimoto Y (2016) A multicenter observational study of the effectiveness of antiarrhythmic agents in ventricular arrhythmias: A propensity-score adjusted analysis. J Arrhythm 32(3):186\u2013190. https:\/\/doi.org\/10.1016\/j.joa.2016.01.004","journal-title":"J Arrhythm"},{"issue":"1","key":"9882_CR7","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.4022\/jafib.1839","volume":"11","author":"T Kawaji","year":"2018","unstructured":"Kawaji T, Shizuta S, Yamagami S, Aizawa T, Komasa A, Yoshizawa T, Kato M, Yokomatsu T, Miki S, Ono K, Kimura T (2018) Clinical utility of intravenous nifekalant injection during radiofrequency catheter ablation for persistent atrial fibrillation. J Atr Fibrillation 11(1):1839. https:\/\/doi.org\/10.4022\/jafib.1839","journal-title":"J Atr Fibrillation"},{"key":"9882_CR8","doi-asserted-by":"publisher","first-page":"105385","DOI":"10.1016\/j.ejps.2020.105385","volume":"151","author":"J Zhang","year":"2020","unstructured":"Zhang J, Zan Y, Huo H, Liu Y, Tang Y, Han Y (2020) Population pharmacokinetic\/pharmacodynamic modelling of nifekalant in healthy Chinese volunteers. Eur J Pharm Sci 151:105385. https:\/\/doi.org\/10.1016\/j.ejps.2020.105385","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"9882_CR9","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/cpt.60","volume":"97","author":"B Darpo","year":"2015","unstructured":"Darpo B, Benson C, Dota C, Ferber G, Garnett C, Green CL, Jarugula V, Johannesen L, Keirns J, Krudys K, Liu J, Ortemann-Renon C, Riley S, Sarapa N, Smith B, Stoltz RR, Zhou M, Stockbridge N (2015) Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase. Clin Pharmacol Ther 97(4):326\u2013335. https:\/\/doi.org\/10.1002\/cpt.60","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"9882_CR10","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/bph.13436","volume":"173","author":"GK Panicker","year":"2016","unstructured":"Panicker GK, Karnad DR, Kadam P, Badilini F, Damle A, Kothari S (2016) Detecting moxifloxacin-induced QTc prolongation in thorough QT and early clinical phase studies using a highly automated ECG analysis approach. Brit J Pharmacol 173(8):1373\u20131380. https:\/\/doi.org\/10.1111\/bph.13436","journal-title":"Brit J Pharmacol"},{"issue":"12","key":"9882_CR11","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s00228-015-1959-z","volume":"71","author":"RR Shah","year":"2015","unstructured":"Shah RR, Maison-Blanche P, Duvauchelle T, Robert P, Denis E (2015) Establishing assay sensitivity in QT studies: experience with the use of moxifloxacin in an early phase clinical pharmacology study and comparison with its effect in a thorough QT study. Eur J Clin Pharmacol 71(12):1451\u20131459. https:\/\/doi.org\/10.1007\/s00228-015-1959-z","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"9882_CR12","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s40264-015-0325-5","volume":"38","author":"B Darpo","year":"2015","unstructured":"Darpo B, Garnett C, Keirns J, Stockbridge N (2015) Implications of the IQ-CSRC prospective study: time to revise ICH E14. Drug Saf 38(9):773\u2013780. https:\/\/doi.org\/10.1007\/s40264-015-0325-5","journal-title":"Drug Saf"},{"key":"9882_CR13","doi-asserted-by":"publisher","first-page":"293564","DOI":"10.1155\/2015\/293564","volume":"2015","author":"G Ferber","year":"2015","unstructured":"Ferber G, Lorch U, Taubel J (2015) The power of phase i studies to detect clinical relevant QTc prolongation: a resampling simulation study. Biomed Res Int 2015:293564. https:\/\/doi.org\/10.1155\/2015\/293564","journal-title":"Biomed Res Int"},{"issue":"4","key":"9882_CR14","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/anec.12227","volume":"20","author":"G Ferber","year":"2015","unstructured":"Ferber G, Zhou M, Darpo B (2015) Detection of QTc effects in small studies\u2013implications for replacing the thorough QT study. Ann Noninvasive Electrocardiol 20(4):368\u2013377. https:\/\/doi.org\/10.1111\/anec.12227","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"19","key":"9882_CR15","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1093\/eurheartj\/ehi312","volume":"26","author":"SM Straus","year":"2005","unstructured":"Straus SM, Sturkenboom MC, Bleumink GS, Dieleman JP, van der Lei J, de Graeff PA, Kingma JH, Stricker BH (2005) Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 26(19):2007\u20132012. https:\/\/doi.org\/10.1093\/eurheartj\/ehi312","journal-title":"Eur Heart J"},{"issue":"15","key":"9882_CR16","first-page":"2028","volume":"123","author":"J Wang","year":"2010","unstructured":"Wang J, Hua W, Zhu J, Yang YM, Wang FZ, Pu JL, Chen KP, Zhang S (2010) Nifekalant hydrochloride terminating sustained ventricular tachycardia accompanied with QT dispersion prolongation. Chin Med J 123(15):2028\u20132033","journal-title":"Chin Med J"},{"key":"9882_CR17","unstructured":"ICH (2015) ICH E14 Guideline: the clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrythmic drugs questions and answers (R3). ICH Official web site. https:\/\/database.ich.org\/sites\/default\/files\/E14_Q%26As_R3_Q%26As.pdf. Accessed 15 May 2022"},{"key":"9882_CR18","unstructured":"ICH (2020) Clinical and nonclinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential questions and answers E14\/S7B. ICH Official web site. https:\/\/database.ich.org\/sites\/default\/files\/E14-S7B_QAs_Step4_2022_0221.pdf. Accessed 15 May 2022"},{"issue":"3","key":"9882_CR19","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","volume":"45","author":"C Garnett","year":"2018","unstructured":"Garnett C, Bonate PL, Dang Q, Ferber G, Huang D, Liu J, Mehrotra D, Riley S, Sager P, Tornoe C, Wang Y (2018) Scientific white paper on concentration-QTc modeling. J Pharmacokinet Pharmacodyn 45(3):383\u2013397. https:\/\/doi.org\/10.1007\/s10928-017-9558-5","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"9882_CR20","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1097\/00005344-200211000-00011","volume":"40","author":"M Igawa","year":"2002","unstructured":"Igawa M, Aonuma K, Okamoto Y, Hiroe M, Hiraoka M, Isobe M (2002) Anti-arrhythmic efficacy of nifekalant hydrochloride, a pure class III anti-arrhythmic agent, in patients with healed myocardial infarction and inducible sustained ventricular tachycardia. J Cardiovasc Pharm 40(5):735\u2013742. https:\/\/doi.org\/10.1097\/00005344-200211000-00011","journal-title":"J Cardiovasc Pharm"},{"issue":"12","key":"9882_CR21","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3760\/cma.j.issn.0253-3758.2019.12.004","volume":"47","author":"F Li","year":"2019","unstructured":"Li F, Xia Z, Yu JH, Chen Q, Hu JZ, Zhu B, Xia ZR, Huang QH, Li JX, Hong K, Wu YQ, Cheng XS (2019) Cardioversion efficacy of nifekalan in patients with sustained atrial fibrillation after radiofrequency ablation. Zhonghua Xin Xue Guan Bing Za Zhi 47(12):963\u2013968. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-3758.2019.12.004","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"4","key":"9882_CR22","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1536\/ihj.39.457","volume":"39","author":"N Naitoh","year":"1998","unstructured":"Naitoh N, Tagawa M, Yamaura M, Taneda K, Furushima H, Aizawa Y (1998) Comparison of electrophysiologic effects of intravenous E-4031 and MS-551, novel class III antiarrhythmic agents, in patients with ventricular tachyarrhythmias. Jpn Heart J 39(4):457\u2013467. https:\/\/doi.org\/10.1536\/ihj.39.457","journal-title":"Jpn Heart J"},{"issue":"10","key":"9882_CR23","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1253\/circj.69.1237","volume":"69","author":"T Katoh","year":"2005","unstructured":"Katoh T, Mitamura H, Matsuda N, Takano T, Ogawa S, Kasanuki H (2005) Emergency treatment with nifekalant, a novel class III anti-arrhythmic agent, for life-threatening refractory ventricular tachyarrhythmias: post-marketing special investigation. Circ J 69(10):1237\u20131243. https:\/\/doi.org\/10.1253\/circj.69.1237","journal-title":"Circ J"},{"issue":"8","key":"9882_CR24","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/j.1540-8167.2012.02292.x","volume":"23","author":"M Chinushi","year":"2012","unstructured":"Chinushi M, Sato A, Izumi D, Furushima H (2012) Nifekalant enlarged the transmural activation-recovery interval difference as well as the peak-to-end interval on surface ECG in a patient with short-QT syndrome. J Cardiovasc Electrophysiol 23(8):877\u2013880. https:\/\/doi.org\/10.1111\/j.1540-8167.2012.02292.x","journal-title":"J Cardiovasc Electrophysiol"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-023-09882-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-023-09882-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-023-09882-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T14:11:59Z","timestamp":1708611119000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-023-09882-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["9882"],"URL":"https:\/\/doi.org\/10.1007\/s10928-023-09882-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3085145\/v1","asserted-by":"object"}]},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,11]]},"assertion":[{"value":"20 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}